Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria

NCT01426815 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Peripheral Spondylarthritis

Interventions

DRUG: Placebo
DRUG: Golimumab

Sponsor

University Hospital, Ghent

Collaborators

[object Object]